Compare Alcon AG (ALC) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Symbotic Inc — how do they compare? Alcon AG trades at $75 (market cap $35.19B), while Symbotic Inc trades at $41.86 (market cap $5.21B). The key difference: Alcon AG is far larger — about 6.8× Symbotic Inc's market cap, and Alcon AG pays a 0.49% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals.
| ALC | SYM | |
|---|---|---|
Market Cap | $35.19B | $5.21B |
Sector | Health | Technology |
52-Week High | $90.12 | $87.30 |
52-Week Low | $62.02 | $38.57 |
Enterprise Value | $39.03B | $3.46B |
Dividend Yield | 0.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $71.81, up 3.26% today, with a bullish technical signal supported by moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.84, beating estimates, and raised its profit guidance on August 11, 2026, citing strong product launches. Revenue grew to $10.4B in 2025, though net income margin dipped to 9.42%. Valuation ratios include a P/E of 43 and P/S of 3.34, reflecting premium pricing.
Outlook is positive with analyst consensus at 54% buy ratings and a 27.8% upside target, but risks include margin pressure and high debt. The stock offers growth potential from innovation but faces competitive and macroeconomic headwinds.
SYM trades at $40.18, down 1.46% with bearish technical signals despite analyst optimism. Recent Q3 2026 earnings missed estimates at $0.09 vs. $0.13 expected, though revenue grew 21.7% year-over-year. The company shows weak profitability with a 0.31% net margin but maintains strong cash flow generation of $517 million in 2025. Technical indicators show bearish momentum with support at $39 and resistance at $42.
Outlook remains mixed with 61% analyst buy ratings and $60 consensus target suggesting 49% upside, but execution risks persist after recent earnings misses. Key catalysts include margin expansion and system deployments, while risks include competitive pressure and volatile earnings performance. The stock offers growth potential but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
